The Guardant360® Assay Receives Expedited Access Pathway Designation for Breakthrough Devices from FDA

REDWOOD CITY, Calif., Feb. 15, 2018 /PRNewswire/ -- The Guardant360® assay, the leading comprehensive liquid biopsy, received an Expedited Access Pathway (EAP) designation from the United States Food and Drug Administration, Guardant Health announced. If approved, the Guardant360 assay...